This article explores the evolution of FDA’s approach to inspections of drug and biologics manufacturing facilities during the COVID-19 pandemic.
Kalah Auchincloss
Advertisement
Kalah Auchincloss, senior vice-president and deputy general counsel, Greenleaf Health, Inc.
Articles by Kalah Auchincloss
Advertisement
Latest Updated Articles
- FDA Inspections During COVID-19: A Brave New World
Published: April 14th 2021 | Updated:
Advertisement
Advertisement
